|
Achillion Pharmaceuticals is looking for the Achilles heel of infectious disease. The firm is developing biopharmaceutical treatments for infectious diseases, including antiviral treatments for HIV infection and hepatitis C, as well as antibacterials for fighting drug-resistant hospital-based infections. Lead candidate elvucitabine is in clinical trials for the treatment of HIV; the drug is designed specifically for patients who have become resistant to existing antiviral drugs. Achillion is working in collaboration with biotech firm Gilead Sciences to develop a possible treatment for chronic hepatitis C. Another candidate in development is aimed at combating staph and other drug-resistant infections.
|
| | | Contact Information | |
Address: |
300 George St.
New Haven, CT 06511
| | Phone: | 203-624-7000 | | Fax: | 203-624-7003 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | (-0.20 M) | | Employees (2008): | 54 | | Employee Growth (1 yr): | (-10.00%) |
|
|
Key People
| | • |
President, CEO, and Director:
Michael D. Kishbauch
| | • |
VP and CFO:
Mary Kay Fenton
| | • |
VP Business Development and Chief Commercial Officer:
Joseph (Joe) Truitt
|
|
|
